1. Home
  2. PRG vs ARDX Comparison

PRG vs ARDX Comparison

Compare PRG & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$31.33

Market Cap

1.1B

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
ARDX
Founded
2020
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PRG
ARDX
Price
$31.33
$5.90
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$47.50
$15.14
AVG Volume (30 Days)
328.6K
3.0M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
1.66%
N/A
EPS Growth
N/A
N/A
EPS
3.59
N/A
Revenue
$2,409,223,000.00
$2,607,000.00
Revenue This Year
$23.77
$37.75
Revenue Next Year
$7.91
$34.24
P/E Ratio
$8.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.47
$3.50
52 Week High
$41.14
$8.40

Technical Indicators

Market Signals
Indicator
PRG
ARDX
Relative Strength Index (RSI) 54.05 45.34
Support Level $29.80 $5.49
Resistance Level $31.52 $6.23
Average True Range (ATR) 1.02 0.24
MACD 0.34 -0.01
Stochastic Oscillator 62.04 25.31

Price Performance

Historical Comparison
PRG
ARDX

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: